Accelerated fractionation vs. conventional fractionation radiation therapy for glottic cancer of T1-2N0M0 Phase III study (JCOG0701)

INTERVENTION: A: Conventional fractionation radiation therapy (2 Gy/fr; T1:66 Gy/33 fr, T2:70 Gy/35 fr) B: Accelerated fractionation radiation therapy (2.4 Gy/fr; T1: 60 Gy/25 fr, T2: 64.8 Gy/27 fr) CONDITION: T1‐2N0M0 glottic cancer PRIMARY OUTCOME: 3‐year progression‐free survival SECONDARY OUTCOME: overall survival, local progression‐free survival, disease‐free survival, survival with preserved voice function, complete response rate, proportion of treatment completion in specific term, adverse events INCLUSION CRITERIA: 1) Primary tumor site is vocal cord. 2) Histologically proven squamous cell carcinoma. 3) Extent of primary tumor is evaluated as T1 or T2 without impaired cord morbidity. 4) Clinical N0/M0. 5) Planned radiation therapy fulfill limitation of overall treatment time. 6) Aged 20 to 80 years old. 7) Performance status of 0 or 1. 8) No prior surgery or radiation therapy against larynx. 9) No prior chemotherapy against any malignancies. 10) Sufficient organ functions. 11) Written informed consent.